Shortly before it reported fourth quarter and full-year earnings results, Thermo Fisher Scientific (NYSE: TMO) announced the sale of its anatomical pathology (AP) business for $1.14 billion. The buyer, Tokyo-based PHC Holdings Corporation, is a global healthcare company developing and manufacturing medical equipment and products across diabetes care, diagnostics, life sciences and healthcare information technology. […]
Contract research organizations (CROs) are hot targets this year. The heavy demand by pharma and biotech companies is attracting large private equity buyers.
Patheon N.V., formerly Patheon, Inc., has been acquired by Thermo Fisher Scientific for $7.2 billion. This deal marks the largest year-to-date in the contract development and manufacturing market.